The estimated Net Worth of Lambert Shiu is at least $4.35 million dollars as of 9 October 2023. Mr Shiu owns over 2,750 units of Penumbra Inc stock worth over $3,938,166 and over the last 5 years he sold PEN stock worth over $0. In addition, he makes $413,209 as Chief Accounting Officer at Penumbra Inc.
Sign up
Mr Shiu PEN stock SEC Form 4 insiders trading
Mr has made over 2 trades of the Penumbra Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 2,750 units of PEN stock worth $33,990 on 9 October 2023.
The largest trade he's ever made was exercising 2,750 units of Penumbra Inc stock on 9 October 2023 worth over $33,990. On average, Mr trades about 365 units every 38 days since 2020. As of 9 October 2023 he still owns at least 19,466 units of Penumbra Inc stock.
You can see the complete history of Mr Shiu stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Lambert Shiu biography
Lambert Shiu is the Chief Accounting Officer at Penumbra Inc.
What is the salary of Mr Shiu?
As the Chief Accounting Officer of Penumbra Inc, the total compensation of Mr Shiu at Penumbra Inc is $413,209. There are 8 executives at Penumbra Inc getting paid more, with Johanna Roberts having the highest compensation of $2,556,370.
How old is Mr Shiu?
Mr Shiu is 41, he's been the Chief Accounting Officer of Penumbra Inc since . There are 15 older and 2 younger executives at Penumbra Inc. The oldest executive at Penumbra Inc is Don Kassing, 78, who is the Presiding Independent Director.
What's Mr Shiu's mailing address?
Lambert's mailing address filed with the SEC is ONE PENUMBRA PLACE, , ALAMEDA, CA, 94502.
Insiders trading at Penumbra Inc
Over the last 9 years, insiders at Penumbra Inc have traded over $197,637,326 worth of Penumbra Inc stock and bought 700 units worth $109,480 . The most active insiders traders include Adam Elsesser, Arani Bose et James Robert Pray. On average, Penumbra Inc executives and independent directors trade stock every 9 days with the average trade being worth of $2,030,383. The most recent stock trade was executed by Harpreet Grewal on 4 September 2024, trading 782 units of PEN stock currently worth $159,614.
What does Penumbra Inc do?
penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.
What does Penumbra Inc's logo look like?
Complete history of Mr Shiu stock trades at Penumbra Inc
Penumbra Inc executives and stock owners
Penumbra Inc executives and other stock owners filed with the SEC include:
-
Johanna Roberts,
Executive Vice President, General Counsel, Secretary -
Maggie Yuen,
Chief Financial Officer -
Adam Elsesser,
Chairman of the Board, Chief Executive Officer -
Lynn Rothman,
Executive Vice President, Chief Business Officer -
Maggie S. Yuen,
Chief Financial Officer -
James Pray,
President, International -
Arani Bose,
Chief Innovator, Director -
Johanna Roberts,
Exec. VP, Gen. Counsel & Sec. -
Lambert Shiu,
Chief Accounting Officer -
Janet Leeds,
Independent Director -
Surbhi Sarna,
Independent Director -
Adam Elsesser,
Co-Founder, Chairman, Pres & CEO -
Harpreet Grewal,
Independent Director -
Bridget O'Rourke,
Independent Director -
Thomas Wilder,
Independent Director -
Don Kassing,
Presiding Independent Director -
Lambert Shiu,
Chief Accounting Officer -
Gita Barry,
Exec. VP & GM of Immersive Healthcare -
Ben Tompkins,
Exec. VP of Devel. -
Shruthi Narayan,
Director of Marketing - Vascular -
Dr. Arani Bose M.D.,
Co-Founder & Director -
Jee Hamlyn-Harris,
Investor Relations Officer -
Corey L. Teigen M.D.,
Chief Scientific Officer -
Ben Sorci,
Exec. VP of Operations -
Kevin James Sullivan,
Director -
Robert D. Evans,
EVP, Gen. Counsel & Secretary -
Daniel Donen Davis,
President, North America -
Sridhar Kosaraju,
President -
Walter Charles Wang,
Director